185 related articles for article (PubMed ID: 31815769)
1. Mechanisms of PARP inhibitor resistance in ovarian cancer.
Kubalanza K; Konecny GE
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):36-41. PubMed ID: 31815769
[TBL] [Abstract][Full Text] [Related]
2. Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
McCann KE
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):12-17. PubMed ID: 30540581
[TBL] [Abstract][Full Text] [Related]
3. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of PARP inhibitor sensitivity and resistance.
D'Andrea AD
DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
[TBL] [Abstract][Full Text] [Related]
6. Leveraging DNA repair deficiency in gynecologic oncology.
Walsh CS; Hodeib M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
[TBL] [Abstract][Full Text] [Related]
7. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
8. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
10. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Klotz DM; Wimberger P
Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
[TBL] [Abstract][Full Text] [Related]
11. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
12. Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer.
Kim YN; Shim Y; Seo J; Choi Z; Lee YJ; Shin S; Kim SW; Kim S; Choi JR; Lee JY; Lee ST
Clin Cancer Res; 2023 Jul; 29(14):2725-2734. PubMed ID: 37067525
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Huang TT; Burkett SS; Tandon M; Yamamoto TM; Gupta N; Bitler BG; Lee JM; Nair JR
Oncogene; 2022 Nov; 41(46):5020-5031. PubMed ID: 36224341
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
16. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
17. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
19. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
20. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
Karakashev S; Fukumoto T; Zhao B; Lin J; Wu S; Fatkhutdinov N; Park PH; Semenova G; Jean S; Cadungog MG; Borowsky ME; Kossenkov AV; Liu Q; Zhang R
Cancer Cell; 2020 Feb; 37(2):157-167.e6. PubMed ID: 32004442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]